Pieris Pharmaceuticals
PIRS
Market cap $20.6M

15.59 USD

+0.15

0.97%

At close Nov 19, 4:00 PM EST

1 day

0.97%

5 days

-5.34%

1 month

-7.20%

3 months

-7.64%

6 months

39.45%

Year to date

4.63%

1 year

-11.67%

5 years

-94.86%

10 years

-92.91%

About: Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.

Employees: 50

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,735 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

182% more capital invested

Capital invested by funds: $3.58M [Q2] → $10.1M (+$6.51M) [Q3]

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

17.37% more ownership

Funds ownership: 28.51% [Q2] → 45.88% (+17.37%) [Q3]

14% more funds holding

Funds holding: 21 [Q2] → 24 (+3) [Q3]

71% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 7

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for PIRS.

See Analyst Rankings

Financial journalist opinion

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

Poster presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of the Phase 3 SELVA study Poster presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of the Phase 3 SELVA study

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations

FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts

Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations

PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Palvella Therapeutics, Inc. is fair to Pieris shareholders. Pre-merger Pieris shareholders are expected to own approximately 18% of the combined company. Halper Sadeh encourages Pieris shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halper.

PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS

NEW YORK , Aug. 16, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders

NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders

NEW YORK , Aug. 14, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Kellanova (NYSE: K)'s sale to Mars, Incorporated for $83.50 per share in cash. If you are a Kellanova shareholder, click here to learn more about your legal rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceutical s , Inc. ( Nasdaq : PIRS ) , relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pieris Pharmaceuticals, Inc. (NasdaqCM: PIRS) (the “Company”) and Palvella Therapeutics, Inc. Upon completion of the proposed transaction, Pieris shareholders are expected to own approximately 18% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequ.

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.

NEW YORK , July 24, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and its board of directors concerning the proposed acquisition of the company by Palvella Therapeutics, Inc. Pieris Pharmaceuticals stockholders are expected to own approximately 18% of the combined company. The transaction is expected to close in the fourth quarter of 2024.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.

Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders

MILWAUKEE, July 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Pieris (Nasdaq: PIRS) for possible breaches of fiduciary duty and other violations of law in its transaction with Palvella. Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders

See News Rankings

Charts implemented using Lightweight Charts™